ATOSAtossa Therapeutics Inc
$2.46
$0.125
(4.84%)
Closed $2.46
$0.05
(2.03%)
After Hours
Reported EarningsMay 8
Mkt Cap$22.26M
Vol644,745.00
Fundamentals
Mkt Cap
$22.26M
Volume
-
52W High
$19.35
52W Low
$2.45
PE Ratio
-0.56
Avg. Volume
52,975.81
EPS (Annual)
-$4.04
Rev/Employee
$0.00
Earnings
May 08
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR Newswire SEATTLE, June 12, 2026 $4.5 million upfront with up to an additional...
PR Newswire
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR Newswire SEATTLE, June 11, 2026 $4.5 million upfront with up to an additional $12 million of...
PR Newswire
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial PR...
PR Newswire
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy PR...
PR Newswire
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer Atossa Therapeutics to Host Virtual KOL Event Featuring...
PR Newswire
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR...
PR Newswire
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for...
PR Newswire
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug
The company said that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer.
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest ATOS News
ViewAtossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
PR Newswire
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
PR Newswire
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
PR Newswire
Advertisement|Remove ads.